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a  b  s  t  r  a  c  t
Objective: To perform a cross-cultural adaptation and validation of the Proﬁle of Fatigue
and Discomfort – Sicca Symptoms Inventory (short form) (PROFAD-SSI-SF) questionnaire
assessing the subjective aspects of the symptoms of primary Sjögren syndrome (pSS), for
the  Brazilian Portuguese language.
Method: Conceptual, of the item, semantic and operational equivalences were evaluated.
The Brazilian version of PROFAD-SSI-SF was administered to 62 women with pSS according
to  the European-American consensus 2002 to assess measurement equivalence. -Cronbach
was  used for internal consistency; intraclass correlation coefﬁcient (ICC) for intraobserver
reproducibility; and Spearman correlation coefﬁcient for validity by comparing with Patient
Global Assessment (PaGA), EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI),
Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-F) and EuroQOL
(EQ-5D).
Results: The internal consistency of PROFAD, SSI and total score was 0.80; 0.78; and 0.87,
respectively. The intraobserver reproducibility of total PROFAD was 0.89; of total SSI was
0.86; and total score was 0.89. In terms of validity, PROFAD correlated signiﬁcantly with PaGA(r  = 0.50), FACIT-F (r = 0.59), ESSPRI (r = 0.58) and all domains of EQ-5D, with the exception ofMobility. On the other hand, SSI correlated signiﬁcantly with PaGA (r = 0.43), FACIT-F (r = 0.57),
ESSPRI (r = 0.55) and most domains of EQ-5D. The total score of PROFAD-SSI-SF had a non-
statistically signiﬁcant correlation only with Mobility domain and with 1–100 range of EQ-5D.
 Institution: Rheumatology Outpatient Clinic, Hospital Universitário Cassiano Antônio de Moraes (HUCAM), Universidade Federal do
spírito Santo (UFES), Vitória, ES, Brazil.
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E-mail: val.valim@gmail.com (V. Valim).
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Conclusion: The Portuguese version of PROFAD-SSI-SF proved to be an adaptable, repro-
ducible and valid tool for the Brazilian Portuguese language.
© 2014 Elsevier Editora Ltda. All rights reserved.
Avaliac¸ão  da  fadiga  e  da  secura  na  síndrome  de  Sjögren  primária:  versão
brasileira  do  “Proﬁle  of  Fatigue  and  Discomfort  –  Sicca  Symptoms







r  e  s  u  m  o
Objetivo: Realizar a adaptac¸ão transcultural e a validac¸ão do Proﬁle of Fatigue and Dis-
comfort – Sicca Symptoms Inventory (short form) (PROFAD-SSI-SF), questionário que avalia
os  aspectos subjetivos dos sintomas da síndrome de Sjögren primária (SSp), para a língua
portuguesa brasileira.
Método: Foi avaliada a equivalência conceitual, de item, semântica e operacional. A versão
brasileira do Profad-SSI-SF foi aplicada a 62 mulheres com SSp conforme consenso europeu-
americano de 2002 para avaliar a equivalência de mensurac¸ão. Foi usado o -Cronbach
para  consistência interna; coeﬁciente de correlac¸ão intraclasse (ICC) para reprodutibilidade
intraobservador; e coeﬁciente de correlac¸ão de Spearman para validade correlacionado com
o  Patient Global Assessment (PaGA), EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI),
Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-F) e EuroQOL (EQ-5D).
Resultados: A consistência interna do PROFAD, do SSI e da pontuac¸ão total foi de 0,80, 0,78 e
0,87,  respectivamente. A reprodutibilidade intraobservador do PROFAD total foi de 0,89; do
SSI  total de 0,86 e da pontuac¸ão total de 0,89. Na validade, o PROFAD apresentou correlac¸ão
signiﬁcativa com o PaGA (r = 0,50), FACIT-F (r = 0,59), ESSPRI (r = 0,58) e todos os domínios
do  EQ-5D, com excec¸ão da mobilidade. Já o SSI apresentou correlac¸ão signiﬁcativa com
o  PaGA (r = 0,43), FACIT-F (r = 0,57), ESSPRI (r = 0,55) e a maioria dos domínios do EQ-5D. A
pontuac¸ão  total do PROFAD-SSI-SF só não obteve correlac¸ão estatisticamente signiﬁcante
com  o domínio mobilidade e escala 1 a 100 do EQ-D5.
Conclusão: A versão em português do PROFAD-SSI-SF mostrou ser adaptável, reprodutível e
válida para a língua portuguesa brasileira.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
ever, a long questionnaire can be tiresome for some patientsIntroduction
Primary Sjögren’s syndrome (pSS) is a systemic disorder
characterized by lymphocytic inﬁltration and progressive
destruction of exocrine glands; however, the inﬂammatory
process can affect any organ. The clinical manifestations can
be split into two aspects: (1) benign, but disabling, ﬁndings, as
dryness, pain and fatigue, affecting the majority of patients
and (2) systemic ﬁndings that can be potentially severe, affect-
ing about 20–40% of patients.1 Due to the lack of universally
accepted classiﬁcation criteria, the evaluation of the incidence
and prevalence of the disease varies signiﬁcantly, depending
on the criteria used. The prevalence may range from 0.03%
to 2.7% of the population.2 In the Brazilian population, the
prevalence, according to the American-European criteria, is
0.17%.3
In recent decades, experts established a consensus that it
is critical to obtain objective measures of saliva4 and tear5 pro-
duction, as well as to assess dryness and fatigue symptoms,
quality of life and activity and disease damage, through valid
and reliable assessment instruments,6–8 both to improve theaccuracy of clinical assessment before and after treatment, as
to enable conducting clinical trials.
There are few self-assessment instruments focused on the
perception of the patient to assess the subjective aspects of
his/her symptoms in this disease, as the Proﬁle of Fatigue and
Discomfort (PROFAD),9,10 Sicca Symptoms Inventory (SSI)10,11
and the most recently tool created by EULAR and already val-
idated for Brazilian Portuguese language, the EULAR Sjögren’s
Syndrome Patient Reported Index (ESSPRI),1,12 which is a ques-
tionnaire consisting of three domains: fatigue, dryness and
pain, assessed by a scale numbered from 0 to 10, with equal
weights, and whose ﬁnal score is the average of the scores of
the three domains.
The Proﬁle of Fatigue and Discomfort – Sicca Symptoms
Inventory (long form) (PROFAD-SSI-LF) consists of 64 questions
scored from 0 to 7 for eight domains: somatic fatigue, men-
tal fatigue, arthralgia, vascular dysfunction, ocular dryness,
oral dryness, vaginal dryness and cutaneous dryness.9,10 How-and expensive in clinical trials. Thus, a shorter version was
developed and validated: the Proﬁle of Fatigue and Discom-
fort – Sicca Symptoms Inventory (short form) (PROFAD-SSI-SF),
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hich consists of 19 questions distributed in the same 8
omains of the long version, having two scores, one for PRO-
AD and the other for SSI. PROFAD has nine items split into
our domains: cutaneous fatigue, mental fatigue, arthralgia
nd vascular, and SSI has 10 items split into four domains:
cular dryness, oral dryness, vaginal dryness, and cutaneous
ryness. In both tools the ﬁnal score is the sum of its four
omains, and varies from 0 to 28.11 Its advantage is the dis-
inction of fatigue in physical and mental types, as well as in
ites of dryness, which do not always appear simultaneously
nd at the same intensity.
Recent studies in which PROFAD, SSI and ESSPRI were
orrelated showed that all these tools exhibited signiﬁcant
orrelation among themselves and with the patient global
ssessment for disease activity, thus showing conﬁrmation of
onstruct validity.13,14 PROFAD was also validated for other
heumatic diseases, such as systemic lupus erythematosus
nd rheumatoid arthritis, and it has been shown that this
ool have moderate to high sensitivity (65–85%) and speciﬁcity
55–77%).9
Besides the need for validation of this tool, it is critical
hat it has its psychometric properties tested in several lan-
uages and in different populations of patients with pSS. This
ould allow the realization of cross-cultural studies and of
omparisons between national and international studies, thus
roviding the scientiﬁc communication between countries of
ifferent languages.15–17 This study aims to conduct a cross-
ultural adaptation and validation of PROFAD-SSI-SF for the
razilian Portuguese language. An attempt was also made to
valuate the psychometric properties of a total score for the
nstrument, although the original version did not present it.
ethod
his is a cross-sectional observational study approved by the
thics Committee in Research of the Health Science Cen-
er, UFES (Universidade Federal do Espírito Santo), under
pinion number 008/10 and developed in the Sjögren’s Syn-
rome Ambulatory, Rheumatology Outpatient Clinic, Hospital
niversitário Cassiano Antonio de Moraes (HUCAM), Vitória,
spírito Santo.
The procedures for the conduction of a cross-cultural adap-
ation of PROFAD-SSI-SF followed the methodology proposed
y Herdman, Fox-Rushby and Badia (1998),18 which covers six
teps: conceptual, of item, semantic, operational, measure-
ent and functional equivalence.
Conceptual, of item, semantic and operational equiv-
lences of PROFAD-SSI-SF were checked at the time of
ranslation and retranslation (back translation), by a com-
ittee formed by a rheumatologist and a physiotherapist
pecialized in Rheumatology, both used in the management
f pSS and ﬂuent in English, and an English teacher. The
ranslation of PROFAD-SSI-SF was performed independently
y two English language teachers having Portuguese as their
ative language and aware of the purpose of the study. On
etranslation, this version was submitted to a translation into
nglish by two other English teachers having the English as
heir native language and who were unaware of the origi-
al version and of the purpose of the study. To evaluate the 5;5 5(2):113–122 115
semantic equivalence, the Portuguese consensus version was
applied to 20 consecutive patients diagnosed with pSS by a
rheumatologist used in managing patients with pSS.
Sixty-two patients were selected for the evaluation of
measurement equivalence across psychometric properties,
according to Streiner and Norman (2008)19 and Kirshner and
Guyatt (1995) methodology20; the calculation to composing
this sample was based on the use of at least ﬁve patients
per domain of the instrument.21 The inclusion criteria were:
diagnosis of pSS according to the American-European classi-
ﬁcation criteria for Sjögren’s syndrome,22 18 years of age or
over, and signing a free and informed consent term. Patients
with other concomitant autoimmune diseases were excluded.
Disease activity was subjectively assessed as inactive and
active (low, moderate and high activity), according to the onset
or worsening of potentially reversible signs and symptoms of
disease in the last four weeks, deﬁned by a medical expert, as
well as by EULAR Sjögren’s Syndrome Disease Activity Index
(ESSDAI), whose score ranges from 0 to 123.17,23 The psy-
chometric properties evaluated were: reliability (intraobserver
reliability) and construct validity. The 62 patients under-
went clinical evaluation by a physician used in the care of
patients with pSS, with completion of the following instru-
ments: PROFAD-SSI-SF, Patient Global Assessment (PaGA),
ESSPRI, Functional Assessment of Chronic Illness Therapy
Fatigue Subscale (FACIT-F)24,25 and EuroQOL (EQ-5D)26 in a sin-
gle moment (visit 1) and after two days (visit 2).
We opted to replace the self-application of the instru-
ment for a face-to-face interview in the evaluation stages of
semantic equivalence and of measurement, considering that
this change does not invalidate the use of the questionnaire
by self-application27; this could be explained by the lack of
practice of patients in completing self-administered question-
naires, or by their low level of schooling,28 and also to avoid the
exclusion of illiterate patients or those with eye problems.29
-Cronbach was used in the analysis of internal consis-
tency; for intra-observer reproducibility, the intraclass corre-
lation coefﬁcient (ICC) was used. For the construct validity of
the comparison of PROFAD-SSI-SF with PaGA, ESSPRI, FACIT-F
and EQ-5D, the Spearman correlation coefﬁcient was used. In
all analyzes, the level of signiﬁcance was accepted as p ≤ 0.05.
Results
In the phase of conceptual, of item, semantic and operational
equivalence, changes in questions 14 and 19 were introduced.
In question 14, in the study of semantic equivalence, the literal
translation of “blurred vision” would be visão turva; however,
the word turva was replaced by embac¸ada, as this is a term
considered more  popular. Likewise, the term “swollen sali-
vary glands” in question 19 would mean inchac¸o das glândulas
salivares, but glândulas salivares is a technical term difﬁcult to
understand and locate for the Brazilian population; thus, it
was replaced by região no rosto à frente das orelhas e abaixo do
queixo inchados. There was no question or item misunderstood
by more  than 15% of the 20 patients in the pre-test. Thus, the
ﬁnal Brazilian language consensus version was obtained.
In the evaluation of measurement equivalence across
the psychometric properties, 62 female patients with pSS
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Table 1 – Demographic and clinical characteristics of 62
patients with primary Sjögren’s syndrome.
Variables n (%) or Mean ± SD
Age (years) 49.4 ± 11.6
Female gender 62 (100)
Time elapsed from the ﬁrst symptoms (years) 7.2 ± 5.4
Time since diagnosis (years) 3.0 ± 3.3
Interval between symptoms and diagnosis
(years)
4.3  ± 4.9
Systemic manifestations in the last visit 29 (46.8)
Inactive disease 29 (46.8)
Active disease
Low activity 24 (38.7)
Moderate activity 9 (14.5)
ESSDAI 4.95 ± 6.73
Clinical features:






Lymphocytic sialadenitis ≥1 focus-score 56 (90.3)
Anti-Ro 27 (43.6)
Anti-La 12 (19.4)
Previous parotid gland swelling 16 (25.8)SD, standard deviation; ESSDAI, EULAR Sjögren’s Syndrome Disease
Activity Index.
coming from the Sjögren’s Syndrome Ambulatory, Rheuma-
tology Outpatient Clinic HUCAM, were included.
The mean age was 49.4 ± 11.6 years. The duration of illness
was 7.2 ± 5.4 years; 46.8% of the patients had some systemic
manifestation and 97.9% had been medicated with immuno-
suppressive agents in some time (Table 1). Most patients
(56.41%) had a low level of schooling (<8 years), and 8.06%
were illiterate. Most patients exhibited disease activity (53.2%),
however, there was a predominance of low activity disease
(38.7%). This low activity was conﬁrmed by the mean total
score of 4.95 with ESSDAI (0–39), in which 11.3% of patients had
a score ≥12. The mean of PROFAD was 18.68 ± 6.23; of SSI was
18.19 ± 6.40; and of the total score of PROFAD-SSI-SF (obtained
by averaging PROFAD and SSI results) was 18.34 ± 5.69 (Table 2).
The internal consistency of PROFAD, SSI and of the total
score was considered high, and a -Cronbach corresponding
to 0.80; 0.78; and 0.87, respectively, was obtained.
The intraobserver reproducibility of PROFAD was 0.89; of
SSI, 0.86; and of the total score was 0.89, showing high repro-
ducibility. The concordance of the questions and domains
between the two visits was considered as good to excellent
(Table 3).
With respect to the construct validity of PROFAD, statis-
tically signiﬁcant correlations of domains “Somatic fatigue”
and “Arthralgia” with all other variables were obtained. The
domain “Mental fatigue” had a statistically signiﬁcant cor-
relation with PaGA, FACIT-F, ESSPRI (Fatigue, Dryness, and
total) and EQ-D5 (Pain/Discomfort and Anxiety/Depression).
On the other hand, the domain “Vascular” showed a statis-
tically signiﬁcant correlation only with FACIT-F and ESSPRI
(Pain, Dryness and total). As to PROFAD, a lack of statistically
signiﬁcant correlation only occurred with the domain “Mobil-
ity” of EQ-D5 (Table 4). With respect to the construct validity 0 1 5;5 5(2):113–122
of SSI, the domain “Cutaneous dryness” showed a statistically
signiﬁcant correlation only with FACIT-F; the domain “Vagi-
nal dryness” with FACIT-F, ESSPRI (Fatigue, Dryness, and total)
and EQ-D5 (Self care and Usual activities); the domain Ocular
dryness with PaGA, FACIT-F and ESSPRI; and the domain “Oral
dryness”, with all variables. The total score of SSI showed sta-
tistically signiﬁcant correlations with PaGA, FACIT-F, ESSPRI
and EQ-D5 (Mobility, Self care and Usual activities) (Table 5). On
the other hand, the total score of PROFAD-SSI-SF only lacked a
statistically signiﬁcant correlation with the domain “Mobility”
and with 1–100 scale of EQ-D5 (Table 6).
Discussion
The editorial of this journal in 200630 highlighted the impor-
tance of the translation and validation of assessment tools in
rheumatology for the Brazilian Portuguese language, remin-
ding that, with a good-quality instrument available to that
effect, the creation of a new instrument requires a greater
commitment of time and cost. However, it is not enough that
the instrument be simply translated; it is critical an accu-
rate assessment of its translation and cultural adaptation,
as well as an evaluation of its measurement (psychometric)
properties after the completion of this process, even when
such properties have already been demonstrated with the
original instrument, as important cultural differences may be
present.30,31
PROFAD-SSI-SF was originally written in the English lan-
guage, with questions appropriate to its own culture. Hence,
for application of this instrument to our population, we  pro-
ceeded to a cultural equivalence, so that the tool could actually
be adequately interpreted by both patient and evaluator.
Demographic data and clinical characteristics of 62
patients in the stage of measurement equivalence evaluation
were similar to those found in other studies of assessment
tools for pSS (PROFAD, SSI, PROFAD-SSI-SF and ESSPRI) and
their cohorts: prevalence >93% in women, mean age between
47 and 62 years, long disease duration averaging 7.21,9–12 years,
and mean interval between symptoms and diagnosis of 5
years, which demonstrates a long delay time for diagnosis of
this disease, an aspect already reported by others.32
The Brazilian version of PROFAD-SSI-SF has demonstrated
high internal consistency (0.80 and 0.78), as well as in the
validation study of the original version, whose -Cronbach
was 0.99.11 The intraobserver reproducibility (r = 0.69–0.85)
also was considered high, similar to the reproducibility of
the original PROFAD-LF (r = 0.67–0.79), tested 24 h after the
ﬁrst application.9 The reproducibility of the domains “Ocu-
lar dryness” (r = 0.92) and “Oral dryness” (r = 92) in the study
of PROFAD-SSI-SF development was also similar to that in the
present study: 0.83 and 0.92, respectively.33
In the validation study of PROFAD-LF, the questions in
the domain “Somatic fatigue” showed correlation only with
the domains “Vitality” of SF-36 (r = −0.53–0.70) and “Physi-
9cal health” of WHOQOL-BREF (r = −0.62 and r = −0.69), unlike
what was observed in the present study, in which that domain
showed a statistically signiﬁcant, although low, correlation
with all domains of EQ-5D (r = 0.28–0.49).
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Table 2 – Descriptive measures of PROFAD-SSI-SF, ESSPRI, EQ-D5, FACIT-F and PaGA.
Variables Mean (±) Minimum Median Maximum SD
PROFAD
Somatic fatigue 5.37 0.50 6 7 1.72
Mental fatigue 5.1 0 6 7 2.17
Arthralgia 5 0 5.5 7 1.98
Vascular 3.21 0 3.5 7 3.03
Total PROFAD 18.68 1.5 18.63 28 6.23
SSI
Cutaneous dryness 4.79 0  6 7 2.57
Vaginal dryness 4 0 5 7 2.96
Ocular dryness 5.38 0  60 7 1.85
Oral dryness 4.02 0 4.20 7 1.85
Total SSI 18.19 3.53 18.33 28 6.40
PROFAD-SSI-SF, total 18.34 2.52 18.13  27.63 5.69
ESSPRI
Pain 7.9 0 8 10 2.53
Fatigue 6 0 7.5 10 3.8
Dryness 6.54 0 7 10 2.76
Total 6.81 1.33 7. 10 2.12
EQ-5D
Mobility 1.66 1 2 2 0.48
Self care 1.35 1 1 2 0.48
Usual activities 1.68 1 2 3 0.57
Pain/Discomfort 2.18 1 2 3 0.53
Anxiety/Depression 2.05 1 2 3 0.66
Scale 1–100 56.73 0 60 100 24.21
FACIT-F 30.73 1 31 52 11.35
PaGA 7.58 2 8 10 2.15
PROFAD, Proﬁle of Fatigue and Discomfort; SSI, Sicca Symptoms Inventory; PROFAD-SSI-SF, Proﬁle of Fatigue and Discomfort – Sicca Symptoms
Inventory (short form); PaGA, Patient’s Global Assessment; FACIT-F, Functional Assessment of Chronic Illness Therapy Fatigue Subscale; ESSPRI,
EULAR Sjögren’s Syndrome Patient Reported Index; EQ-5D, EuroQOL; SD, standard deviation.
Scores of instruments: PROFAD, 0–28; SSI, 0–28; PROFAD-SSI-SF total, 0–28; ESSPRI 0–10; EQ-5D, domains – 1–3, range – 0–100; FACIT-F, 0–52;
PaGA, 0–10.
Table 3 – Intraobserver reproducibility by questions, domains and total of PROFAD and SSI.
PROFAD SSI
Variables CCI Variables CCI
Questions
Question 1 0.71 Question 10 0.74
Question 2 0.69 Question 11 0.91
Question 3 0.76 Question 12 0.72
Question 4 0.75 Question 13 0.69
Question 5 0.78 Question 14 0.91
Question 6 0.86 Question 15 0.82
Question 7 0.78 Question 16 0.79
Question 8 0.80 Question 17 0.87
Question 9 0.78 Question 18 0.80
Question 19 0.83
Domains
Somatic fatigue 0.85 Cutaneous dryness 0.74
Mental fatigue 0.89 Vaginal dryness 0.91
Arthralgia 0.80 Ocular dryness 0.83
Vascular 0.78 Oral dryness 0.92
PROFAD, total 0.89 SSI total 0.86
PROFAD, Proﬁle of Fatigue and Discomfort; SSI, Sicca Symptoms Inventory; CCI, intraclass correlation coefﬁcient.
118  r e v b r a s r e u m a t o l . 2 0 1 5;5 5(2):113–122
Table 4 – Spearman correlation of PROFAD with PaGA, FACIT-F, ESSPRI and EQ-5D.
Variables PROFAD
Somatic fatigue Mental fatigue Arthralgia Vascular Total
PaGA 0.60a 0.26b 0.66a 0.23 0.50a
FACIT-F 0.72a 0.43a 0.51a 0.37b 0.59a
ESSPRI
Pain 0.43a 0.13 0.66a 0.33b 0.49a
Fatigue 0.45a 0.50a 0.31b 0.21 0.46a
Dryness 0.43a 0.32b 0.42a 0.25b 0.42a
Total 0.53a 0.46a 0.58a 0.32b 0.58b
EQ-5D
Mobility 0.28b −0.03 0.35b 0.06 0.18
Self care 0.49a 0.22 0.31b 0.01 0.27b
Usual activities 0.45a 0.12 0.22 0.13 0.28b
Pain/Discomfort 0.45a 0.29b 0.54a 0.23 0.43a
Anxiety/Depression 0.48a 0.33b 0.31b 0.07 0.29b
Scale 1–100 −0.42a −0.06 −0.36b −0.24 −0.31b
PROFAD, Proﬁle of Fatigue and Discomfort; PaGA, Patient’s Global Assessment; FACIT-F, Functional Assessment of Chronic Illness Therapy
Fatigue Subscale; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; EQ-5D, EuroQOL.
a P < 0.001.
b P < 0.05.
Surprisingly, the domain “Mental fatigue” showed a
signiﬁcant but low correlation with the domain “Anx-
iety/Depression” of EQ-5D (r = 0.33). However, this low
correlation was also observed between the questions of the
domain “Mental fatigue” of the original PROFAD-LF with the
domains “Mental health” of SF-36 (r = −0.27 to −0.44), and “Psy-
chological health” of WHOQOL-BREF (r = −0.32 to −0.47) and
of Hospital Anxiety and Depression Scale (HADS) (r = −0.34 to
0.48).9The domain “Arthralgia” of PROFAD-SSI-SF in this study
showed a signiﬁcant correlation with “Mobility” (r = 0.35) and
“Pain/Discomfort” domains (r = 0.54) of EQ-5D. This was also
Table 5 – Spearman correlation of SSI with PaGA, FACIT-F, ESSP
Variables 
Cutaneous dryness Vaginal dryn
PaGA 0.20 0.16 
FACIT-F 0.31b 0.42a
ESSPRI





Mobility 0.01 0.19 
Self care 0.05 0.35b
Usual activities 0.22 0.33a
Pain/Discomfort 0.07 0.13 
Anxiety/Depression 0.05 0.16 
Scale 1–100 0.107 0.02 
SSI, Sicca Symptoms Inventory; PaGA, Patient’s Global Assessment; FACIT-F
ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; EQ-5D, EuroQO
a P < 0.001.
b P < 0.05.found in the correlation of the questions of “Discomfort”
domain of the original PROFAD-LF with “Pain” domain of SF-
36 (r = 0.65) and “Physical health” domain of WHOQOL-BREF
(r = 0.62).9
In the validation study of ESSPRI, a good correlation
between total score of PROFAD (r = 0.66) and of SSI (r = 0.56)
with PaGA1 was obtained – values similar to those in the
present study (0.50 and 0.43, respectively).
As important as the objective measures is the assess-
ment of pSS symptoms focused on patient’s perception,
both with the aim to determine the clinical improvement
in clinical trials, as to observe the progress of patients in
RI and EQ-5D.
SSI













, Functional Assessment of Chronic Illness Therapy Fatigue Subscale;
L.
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Table 6 – Spearman correlation of PROFAD-SSI-SF total
















PROFAD-SSI-SF, Proﬁle of Fatigue and Discomfort – Sicca Symptoms
Inventory (short form); PaGA, Patient’s Global Assessment; FACIT-F,
Functional Assessment of Chronic Illness Therapy Fatigue Subscale;
























na P < 0.001.
b P < 0.05.
linical practice. Unlike ESSPRI, which has only three ques-
ions (domains), diluting relevant groups of symptoms that
re not always present together, PROFAD evaluates differ-
nt aspects of fatigue (somatic and mental) and discomfort
or favor, avalie o quanto os seus sintomas têm estado ruins na pior fase
 a 7.
. A maior diﬁculdade que eu tive nas duas últimas semanas com 
xausto ou precisando dormir:
enhuma necessidade de descansar 0 1 2 3 
. A maior diﬁculdade que eu tive nas duas últimas semanas para
ara fazer as coisas ou sentindo como se estivesse “numa batalha
enhuma diﬁculdade para comec¸ar
uma  atividade
0 1 2 3 
. A maior diﬁculdade que eu tive nas duas últimas semanas para 
xausto ou sem energia:
enhuma diﬁculdade em continuar
uma  atividade
0 1 2 3 
. A maior diﬁculdade que eu tive nas duas últimas semanas com 
raco:
enhuma falta de forc¸a 0 1 2 3 
. A maior diﬁculdade que eu tive nas duas últimas semanas em n
oncentrar:
enhum problema 0 1 2 3 
. A maior diﬁculdade que eu tive nas duas últimas semanas esqu
enhum problema 0 1 2 3  5;5 5(2):113–122 119
(arthralgia and vascular), and SSI evaluates dryness (cuta-
neous, vaginal dryness, ocular dryness, and oral dryness)
separately, and this turns PROFAD-SSI-SF into a more  conve-
nient tool to use in clinical practice for monitoring patients’
symptoms, and in detailing symptoms in clinical research.
Conclusion
The Brazilian Portuguese version of PROFAD-SSI-SF (Annex 1)
proved to be an adaptable, reproducible and valid tool for the
Portuguese language and can be used in the Brazilian context.
In addition, the total score obtained by averaging PROFAD
and SSI, which is not calculated in the original version, has
demonstrated internal consistency, reproducibility and valid-
ity.
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Annex  1.  Proﬁle  of  Fatigue  and  Discomfort  –
Sicca Symptoms  Inventory  (short  form)
(PROFAD-SSI-SF)  in  Brazilian  Portuguese
language
 nas últimas duas semanas, assinalando um número de
necessidade de descanso,  me  sentindo cansado,
4 5 6 7 tão ruim quanto você puder
imaginar
 comec¸ar uma  atividade, usando muito esforc¸o
”:
4 5 6 7 tão ruim quanto você puder
imaginar
continuar uma  atividade, me  sentindo facilmente
4 5 6 7 tão ruim quanto você puder
imaginar
falta de forc¸a nos meus músculos ou me  sentindo
4 5 6 7 tão ruim quanto você puder
imaginar
ão pensar claramente ou achando difícil me
4 5 6 7 tão ruim quanto você puder
imaginarecendo coisas ou cometendo erros:
4 5 6 7 tão ruim quanto você puder
imaginar
 o l . 2 0 1 5;5 5(2):113–122
 com desconforto nos meus membros,  como, por
lho, ombro) ou nos meus músculos ou dor por todo o
3 4 5 6 7 tão ruim quanto você puder
imaginar
 com dor ou inchac¸o  nos dedos ou punhos:
3 4 5 6 7 tão ruim quanto você puder
imaginar
 com as mãos desconfortavelmente frias:
3 4 5 6 7 tão ruim quanto você puder
imaginar
s com pele seca ou coceira:
3 4 5 6 7 tão ruim quanto você puder
imaginar
s com secura vaginal como, por exemplo: momentos de
:
3 4 5 6 7 tão ruim quanto você puder
imaginar
s com olhos sensíveis como, por exemplo: sensac¸ão de
3 4 5 6 7 tão ruim quanto você puder
imaginar
s com irritac¸ão nos olhos como, por exemplo: nos
 condicionado ou lugares com baixa umidade:
3 4 5 6 7 tão ruim quanto você puder
imaginar
s na visão (mesmo usando óculos) como, por exemplo,
tir televisão ou dirigir à noite, ver a tela do computador
3 4 5 6 7 tão ruim quanto você puder
imaginar
s para me alimentar como, por exemplo: sentir a boca
rir líquidos para engolir os alimentos, alimentos
 ou apreciar menos a comida:
3 4 5 6 7 tão ruim quanto você puder
imaginar
 com garganta ou nariz secos como, por exemplo: boca
 necessidade de ingerir líquido para falar facilmente,
ecando a minha boca:
3 4 5 6 7 tão ruim quanto você puder
imaginar
s com mau  hálito como, por exemplo: sentindo que o
3 4 5 6 7 tão ruim quanto você puder
imaginar
s com necessidade de líquido para molhar a minha
isar beber algo durante a noite, acordar à noite para
3 4 5 6 7 tão ruim quanto você puder
imaginar120  r e v b r a s r e u m a t
7. A maior diﬁculdade que eu tive nas duas últimas semanas
exemplo: desconforto ou dor nas grandes juntas (quadril, joe
corpo:
nenhum problema 0 1 2 
8. A maior diﬁculdade que eu tive nas duas últimas semanas
nenhum problema 0 1 2 
9. A maior diﬁculdade que eu tive nas duas últimas semanas
nenhum problema 0 1 2 
10. A maior diﬁculdade que eu tive nas duas últimas semana
nenhum problema 0 1 2 
11. A maior diﬁculdade que eu tive nas duas últimas semana
desconforto durante a relac¸ão sexual devido à secura vaginal
nenhum problema 0 1 2 
12. A maior diﬁculdade que eu tive nas duas últimas semana
areia, dor, queimac¸ão, coceira ou irritac¸ão.
nenhum problema 0 1 2 
13. A maior diﬁculdade que eu tive nas duas últimas semana
ambientes com fumac¸a, sentindo desconforto ao vento, no ar
nenhum problema 0 1 2 
14. A maior diﬁculdade que eu tive nas duas últimas semana
visão embac¸ada, fraca, com limitac¸ão para leitura, para assis
ou a tela do caixa eletrônico de bancos:
nenhum problema 0 1 2 
15. A maior diﬁculdade que eu tive nas duas últimas semana
seca, diﬁculdade para engolir alimentos, necessidade de inge
entalados, necessidade de retirar restos de alimentos da boca
nenhum problema 0 1 2 
16. A maior diﬁculdade que eu tive nas duas últimas semanas
seca quando respirando, diﬁculdade em falar com boca seca,
sentindo o nariz seco, garganta seca, ou ar condicionado ress
nenhum problema 0 1 2 
17. A maior diﬁculdade que eu tive nas duas últimas semana
hálito tinha cheiro ruim, saliva grossa:
nenhum problema 0 1 2 
18. A maior diﬁculdade que eu tive nas duas últimas semana
boca como, por exemplo: levar algo para beber na cama, prec
urinar, ter necessidade urgente em urinar:
nenhum problema 0 1 2 19. A maior diﬁculdade que eu tive nas duas últimas semanas com outros problemas na boca, como, por exemplo:
úlceras na boca, regiões no rosto à frente das orelhas e abaixo do queixo inchados, engasgando por causa da secura,
mudanc¸a em gostos ou sabores, necessidade de ir ao dentista:
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